These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21170731)

  • 1. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
    Schad M; John J
    Eur J Health Econ; 2012 Apr; 13(2):127-44. PubMed ID: 21170731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discounting and decision making in the economic evaluation of health-care technologies.
    Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
    Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential discounting in the economic evaluation of healthcare programs.
    John J; Koerber F; Schad M
    Cost Eff Resour Alloc; 2019; 17():29. PubMed ID: 31866768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discounting in the economic evaluation of health care interventions.
    Krahn M; Gafni A
    Med Care; 1993 May; 31(5):403-18. PubMed ID: 8501989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On discount rates for economic evaluations in global health.
    Haacker M; Hallett TB; Atun R
    Health Policy Plan; 2020 Feb; 35(1):107-114. PubMed ID: 31625564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating implied rates of discount in healthcare decision-making.
    West RR; McNabb R; Thompson AG; Sheldon TA; Grimley Evans J
    Health Technol Assess; 2003; 7(38):1-60. PubMed ID: 14622489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget allocation and the revealed social rate of time preference for health.
    Paulden M; Claxton K
    Health Econ; 2012 May; 21(5):612-8. PubMed ID: 21438069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economics and ethics in public health?].
    Blum R
    Gesundheitswesen; 1999 Jan; 61(1):1-7. PubMed ID: 10081179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
    Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revolution then evolution: the advance of health economic evaluation in Australia.
    Lopert R; Viney R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):360-6. PubMed ID: 25444293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing role of economic evaluation in valuing medical technologies.
    Rotter JS; Foerster D; Bridges JF
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):711-23. PubMed ID: 23252354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
    Franken M; Koopmanschap M; Steenhoek A
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discounting in health care decision-making: time for a change?
    Sheldon TA
    J Public Health Med; 1992 Sep; 14(3):250-6. PubMed ID: 1419202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of private health insurance on medical care utilization and self-assessed health in Germany.
    Hullegie P; Klein TJ
    Health Econ; 2010 Sep; 19(9):1048-62. PubMed ID: 20665706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review on the appropriate discounting rates for the economic evaluation of gene therapies: whether a specific approach is justified to tackle the challenges?
    Qiu T; Aballéa S; Pochopień M; Toumi M; Dussart C; Yan D
    Int J Technol Assess Health Care; 2024 May; 40(1):e23. PubMed ID: 38725378
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.